BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21501001)

  • 21. Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients.
    Kebapcilar L; Bilgir O; Taner CE; Kebapcilar AG; Kozaci DL; Alacacioglu A; Yildiz Y; Yuksel A; Sari I
    Arch Gynecol Obstet; 2010 Mar; 281(3):539-43. PubMed ID: 19655157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 100 mg acetylsalicylic acid acutely decreases red cell aggregation in women taking oral contraceptives.
    El Bouhmadi A; Laffargue F; Raspal N; Brun JF
    Clin Hemorheol Microcirc; 2000; 22(2):99-106. PubMed ID: 10831061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
    Luque-Ramírez M; Mendieta-Azcona C; del Rey Sánchez JM; Matíes M; Escobar-Morreale HF
    Eur J Endocrinol; 2009 Mar; 160(3):469-80. PubMed ID: 19139031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
    Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
    Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of two different oral contraceptives on homocysteine metabolism in women with polycystic ovary syndrome.
    Cagnacci A; Tirelli A; Renzi A; Paoletti AM; Volpe A
    Contraception; 2006 Apr; 73(4):348-51. PubMed ID: 16531164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
    Rautio K; Tapanainen JS; Ruokonen A; Morin-Papunen LC
    Eur J Endocrinol; 2005 Feb; 152(2):269-75. PubMed ID: 15745936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome.
    Karakurt F; Carlioglu A; Kaygusuz I; Gumus II; Uz B; Akdeniz D
    Arch Gynecol Obstet; 2014 Jan; 289(1):135-40. PubMed ID: 23880889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
    Kabil Kucur S; Gozukara I; Aksoy A; Uludag EU; Keskin H; Kamalak Z; Carlioglu A
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):862-5. PubMed ID: 25402193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obesity and insulin resistance increase plasma viscosity in young women with polycystic ovary syndrome.
    Vervita V; Saltamavros AD; Adonakis G; Tsapanos V; Decavalas G; Georgopoulos NA
    Gynecol Endocrinol; 2009 Oct; 25(10):640-6. PubMed ID: 19557593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
    Acién P; Mauri M; Gutierrez M
    Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
    Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
    J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leptin levels in patients with polycystic ovary syndrome in response to two different oral contraceptive treatments.
    Koyuncu FM; Kuscu NK; Var A; Onur E
    Acta Obstet Gynecol Scand; 2003 Aug; 82(8):767-8. PubMed ID: 12848650
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial.
    Kahraman K; Sükür YE; Atabekoğlu CS; Ateş C; Taşkın S; Cetinkaya SE; Tolunay HE; Ozmen B; Sönmezer M; Berker B
    Arch Gynecol Obstet; 2014 Aug; 290(2):321-8. PubMed ID: 24676694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of a 1-year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism.
    Scheen AJ; Jandrain BJ; Humblet DM; Jaminet CB; Gaspard UJ; Lefèbvre PJ
    Fertil Steril; 1993 Apr; 59(4):797-802. PubMed ID: 8458499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid vein thrombosis in a young woman with methylenetetrahydrofolate reductase gene mutation receiving cyproterone acetate/ethinylestradiol treatment for polycystic ovary syndrome: a case report.
    Nazli Y; Colak N; Aksoy ON; Cakir O
    Blood Coagul Fibrinolysis; 2011 Jun; 22(4):331-3. PubMed ID: 21415709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
    Vrbikova J; Dvorakova K; Hill M; Starka L
    Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
    Glintborg D; Sidelmann JJ; Altinok ML; Mumm H; Andersen M
    Metabolism; 2015 Oct; 64(10):1272-8. PubMed ID: 26194691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.